Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

A biopharmaceutical company focusing on the discovery, development, and commercialization of RNAi therapeutics for treating rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS) diseases.

7

Funding Rounds

$886.1m

Money raised

Overview

A biopharmaceutical company focusing on the discovery, development, and commercialization of RNAi therapeutics for treating rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS) diseases.

Funding

Funding series

Funding Series Analysis

The company Alnylam Pharmaceuticals has raised a total of $886.1m in funding over 7 rounds.

Key Insights:

  • Alnylam Pharmaceuticals Private equity, April 2020: $100m
  • Alnylam Pharmaceuticals Private equity, April 2020: $750m
  • Alnylam Pharmaceuticals Private equity, April 2019: $800k
  • Alnylam Pharmaceuticals Private equity, January 2014: $700k
  • Alnylam Pharmaceuticals funding round, March 2011: $10m
  • Alnylam Pharmaceuticals Venture round, July 2003: $24.6m
Alnylam Pharmaceuticals logo
Alnylam Pharmaceuticals Private equity, April 2020 $100m
Alnylam Pharmaceuticals logo
Alnylam Pharmaceuticals Private equity, April 2020 $750m
Alnylam Pharmaceuticals logo
Alnylam Pharmaceuticals Private equity, April 2019 $800k
Alnylam Pharmaceuticals logo
Alnylam Pharmaceuticals Private equity, January 2014 $700k
Alnylam Pharmaceuticals logo
Alnylam Pharmaceuticals funding round, March 2011 $10m
Alnylam Pharmaceuticals logo
Alnylam Pharmaceuticals Venture round, July 2003 $24.6m

Industries

Alnylam Pharmaceuticals is active in the following industries:
  • Therapeutics
  • Drug discovery
  • Pharmaceutical industry
  • Biotechnology
  • Biomedical engineering
  • Engineering
  • RNA-based and RNA-targeted therapeutics
  • Biology
  • Healthcare
  • Technology